Skip to main content
Clinical Trials/CTRI/2024/08/072504
CTRI/2024/08/072504
Not yet recruiting
未知

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC): An Emerging Market Medical Record Review Study - NI

Pfizer Limited0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: N428- Other specified disorders of prostate
Sponsor
Pfizer Limited
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. New diagnosis of mCRPC during the case selection window (between 15 April 2019 to 14 January 2022, inclusive). mCRPC is defined as the current and/or historical presence of metastases on any imaging modality with evidence of disease progression (a rising PSA or radiographic progression (as defined by the investigator) despite ongoing castration therapy \[LHRH agonist / antagonist or prior surgical
  • orchiectomy]).
  • 2\. Aged at least 18 years upon diagnosis of mCRPC.
  • Of note, patients may be alive or deceased at the date of data abstraction.

Exclusion Criteria

  • Previously enrolled in an interventional trial related to CRPC (patients may have been
  • enrolled in trials of primary treatment and/or hormone\-sensitive prostate cancer).

Outcomes

Primary Outcomes

Not specified

Similar Trials